Research Output Journal of Biological and Applied Science 3(2):9-12, 2024

ROJBAS Publications ONLINE ISSN: 1115-9200

https://rojournals.org/roj-biological-and-applied-science/ PRINT ISSN: 1115-6120

AI-Powered Drug Discovery: Accelerating the Development of New Therapies

Kaggwa Anthony P.

Faculty of Science and Technology Kampala International University Uganda

ABSTRACT

The pharmaceutical industry is at a crossroads, with rising costs and longer development timelines posing significant challenges to the production of new drugs. AI-powered drug discovery emerges as a promising solution, leveraging artificial intelligence to expedite and optimize the drug discovery process. By applying machine learning and deep learning techniques, AI can analyze vast datasets, predict drug efficacy and safety, and even generate novel compounds, significantly reducing the time and cost involved in traditional drug development. This paper explores the role of AI in revolutionizing drug discovery, highlighting its applications in various stages of drug development, the challenges it faces, and its potential to transform the pharmaceutical landscape. Through case studies and analysis of recent advancements, this study underscores the importance of integrating AI in drug discovery to usher in an era of personalized medicine and more efficient therapeutic development.

Keywords: AI-powered drug discovery, Machine learning in pharmaceuticals, Deep learning in drug development, End-to-end drug discovery models, Personalized medicine.

INTRODUCTION

For centuries, the discovery, development, and evaluation of new drugs have been achieved almost exclusively by means of laborious and expensive experiments. These experiments frequently involve the screening of large numbers of molecules for biological activity. However, while the advances in robotics and synthetic chemistry have made it possible to synthesize, screen, and test a greater number of drug candidates, the cost of drug development has continued to rise. As a result, the pharmaceutical industry has become highly risk averse, and the number of new drugs being produced each year has continued to fall. There is now a growing perception that the pharmaceutical industry is in crisis [1]. AI-powered drug discovery refers to the application of AI to the tasks of discovering and designing new drugs, or of finding new capabilities or applications for existing drugs. In particular, the use of AI in drug discovery is often regarded as having the potential to drastically improve pre-clinical drug development. This makes it possible to generate new drug candidates, screen them for activity, and predict efficacy and safety without the need for conducting expensive and time-consuming experiments. Many medicines take decades and billions of dollars to develop, making access to effective and affordable treatments for a variety of diseases a privilege that few can enjoy. AI-driven drug discovery can reduce the time and cost of developing new medicines [2].

THE ROLE OF ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY

The role of AI in drug development has shifted from marginal improvements to ambitious modifications. AI uses terabytes of -omics data to understand biological processes and has developed complex models. We now focus on designing models that work in reality [3]. One of the more recent "buzzwords" of AI-driven drug discovery has been "end-to-end". How can such a linear paradigm truly disrupt standard drug discovery? The point being, when we combine several AI solutions aimed at solving specific problems on drug discovery into a single pipeline (the so-called end-to-end model), we open the possibility to skip some steps of drug discovery (or at least shrink the efforts needed to deal with them) with the potential of generating mutant compounds. The prospect behind an end-to-end approach in AI-driven drug discovery is that one can skip or drastically reduce the number of steps for drug development.

Model-based drug development has to be a cornerstone in the paradigm shift of the pharmaceutical industry because it can act as a lightning rod [4].

MACHINE LEARNING ALGORITHMS FOR DRUG DISCOVERY

ML models are used in drug discovery to identify candidates, predict compound activities, and optimize structures. Development involves steps to minimize toxicity risks and develop administration methods. Discovery involves identifying ideal targets and finding compounds with desired properties. Preclinical and clinical tests are conducted. Machine learning algorithms are used in predictive approaches [5]. This multimodal approach is frequently used to predict the interaction of drugs against a wide variety of viral, bacterial, and fungal targets and to propose new compound structures deduced from virtual screening. The computed system contributes considerably to reducing the time and cost of developing candidate compounds, particularly in the initial phase. Moreover, the atomic structures of enzymes associated with the metabolism of some drugs and others important for the life cycle of the biological targets are available. Machine learning is a subfield of artificial intelligence that allows for the development of empirical systems that improve from experience and data. It has been used extensively for the design of new drug candidates due to its ability to conduct data analysis, recognize patterns, and form predictions [6].

DEEP LEARNING APPLICATIONS IN DRUG DISCOVERY

Deep learning is a powerful technique often applied to model and interpret complex biological data. It can also be used for feature extraction and the construction of disease modules, making it a favorable choice for the discovery of potential drug targets. Bio-AEs, due to their non-linearity modeling ability, are commonly used to learn the relationship between compounds and diseases. Advanced deep learning techniques, such as neural networks or generative adversarial networks, can also be used to generate potential novel compounds. Deep learning is employed to carry out PPI network predictions after the protein structure complex is mined. By predicting the interaction between compounds and cellular proteins through network analysis, deep learning can also be used for the discovery of potential drug targets [7]. Overall, in the field of drug development, deep learning may be employed in target discovery, lead optimization, preclinical validation, and patient stratification. It is well known that several layers of non-linear feature extractors are present in DNNs, which comprise the fundamental technology employed in deep learning. In biological research, deep learning has the capability to process and interpret massive volumes of data. Hidden layer training in other machine learning models usually requires more manual involvement. Several deep learning algorithms, such as CNN or RNN, are currently utilized in the pharmaceutical industry. The primary technique employed in deep learning is to learn new features and representations. Early studies on the automatic extraction of high-order features were commenced by developing deep learning methods for this type of biological data [8].

CHALLENGES AND OPPORTUNITIES IN AI-POWERED DRUG DISCOVERY

The integration of AI into drug discovery and development poses challenges in data quality, collection, compliance, practicality, and ethics. Data collection methods heavily impact model predictions. Ethical and regulatory concerns require transparency and alignment with privacy policies like HIPAA and GDPR. Dataset biases affect AI. The scientific community acknowledges and addresses biases with complex algorithms. Considering the cost of data collection and cloud hosting is crucial. Costs may escalate with increased datasets, particularly in the cloud [9]. Several reports predict a 60-70% reduction in R&D timeline by 2026 with the inclusion of AI. Our proposal aims to decrease investments in unsuccessful drugs and improve exploration in drug discovery. Balancing computer models and lab practices is crucial, given the high cost of transitioning to AI-powered drug discovery. Using AI models can enhance pharmacology, increasing anesthetic production and fostering innovation for personalized therapies. Evaluating if AI would make the same connections as traditional screening approaches is important. AI also reduces costs in optimizing lead molecules, profiling, and predictions. Its prospects are to enhance therapy efficacy, innovation, and drug development. Patient outcomes in drug discovery projects have not significantly improved [10].

CASE STUDIES AND SUCCESS STORIES

Project Alpha – Takeda Deep Learning faced validation across different disease areas with strong clinical validation for rare diseases. 100% match with drug discovery pipeline in first 100 assets [11]. ZebiAI – Balabat. AI drug discovery matching with challenging diseases with a proven need of new mechanism of actions for treatment. AI designed peptides with targeted protein overexpression studies and excellent results [12]. Insilico Medicine, many validated candidates with high clinical progression rate and better in virtual human phase II [13]. AI as Catalyst for new Biotech, AI drug discovery and validation. AI

predicts target in decompensated heart failure based only on transcriptomics [14]. Accutar Biotech. We design somatic peptides and validate in rodent model. Pharmahungary [15]. ALR Technologies. Led XAI engine design and data analysis. Antisan. Developed β-subtype selective degraders of estrogen receptor-alpha for the treatment of primary ovarian insufficiency using our AI drug discovery platform.

FUTURE DIRECTIONS AND ETHICAL CONSIDERATIONS

While deep learning-based methods are powerful predictors, their results are often difficult to interpret, limiting their application in the precision medicine setting. Future improvements in sequence-based deep learning may involve the transition from LSTMs to fully attention-based models. Furthermore, the field of topological data analysis systems could provide an interpretable new feature for neural networks, uncovering the key regions of a molecule or sequence used in making the predictions. Advances in computer architectures, namely the transition from CPU to GPU to TPU, are likely to have further boosts in computational time, making it possible to train more complex networks on ever larger datasets [16]. Success in this domain could also have significant effects on clinical practice. By reducing the cost and time taken to develop novel therapeutic compounds, these predictive techniques create space for an increased number of drugs to be developed, ushering in an era of precision medicine. A resulting consequence may be a complete reboot of healthcare models, focusing on individual constitutions and influencing a population's health span, rather than just managing the eventual diseases of an aging population. Presently, there are ethical considerations about the role of profitable artificial intelligence systems in healthcare, be they in diagnostics or therapeutics. Such systems should be viewed with healthy skepticism, not because they cannot help to alleviate human suffering, but because health is an ethical domain, not a marketplace. Unlike cancer outcomes, the goals of creating strong AI should not be streamlined toward only targeting efficiency and cost savings; rather, there should be a reflection upon secondary effects, such as increased homogeneity in drug development [17].

CONCLUSION

AI-powered drug discovery represents a transformative approach to the development of new therapies, offering the potential to drastically reduce the time and costs associated with traditional drug development processes. By integrating machine learning and deep learning models, AI can predict outcomes with greater accuracy, generate novel drug candidates, and streamline the overall drug discovery pipeline. Despite the challenges related to data quality, ethical considerations, and the need for regulatory compliance, the integration of AI into drug discovery holds immense promise. As AI technologies continue to advance, they are poised to play a pivotal role in the future of pharmaceuticals, enabling the rapid development of personalized therapies and ultimately improving patient outcomes on a global scale

REFERENCES

1. Abd El-Aziz TM, Stockand JD. Recent progress and challenges in drug development against COVID-19 coronavirus (SARS-CoV-2)-an update on the status. Infection. nih.gov
2. Tiwari PC, Pal R, Chaudhary MJ, Nath R. Artificial intelligence revolutionizing drug development: Exploring opportunities and challenges. Drug Development Research. 2023 Dec;84(8):1652-63. researchgate.net
3. Koteluk O, Wartecki A, Mazurek S, Kołodziejczak I, Mackiewicz A. How do machines learn? artificial intelligence as a new era in medicine. Journal of Personalized Medicine. 2021 Jan 7;11(1):32. mdpi.com
4. Han R, Yoon H, Kim G, Lee H et al. Revolutionizing medicinal chemistry: the application of artificial intelligence (AI) in early drug discovery. Pharmaceuticals. 2023. mdpi.com
5. Staszak M, Staszak K, Wieszczycka K, Bajek A, Roszkowski K, Tylkowski B. Machine learning in drug design: Use of artificial intelligence to explore the chemical structure–biological activity relationship. Wiley Interdisciplinary Reviews: Computational Molecular Science. 2022 Mar;12(2):e1568. wiley.com
6. Vatansever S, Schlessinger A, Wacker D, Kaniskan HÜ, Jin J, Zhou MM, Zhang B. Artificial intelligence and machine learning-aided drug discovery in central nervous system diseases: State-of-the-arts and future directions. Medicinal research reviews. 2021 May;41(3):1427-73. wiley.com
7. Gupta R, Srivastava D, Sahu M, Tiwari S, Ambasta RK, Kumar P. Artificial intelligence to deep learning: machine intelligence approach for drug discovery. Molecular diversity. 2021 Aug; 25:1315-60. springer.com

8. Patel SK, George B, Rai V. Artificial intelligence to decode cancer mechanism: beyond patient stratification for precision oncology. Frontiers in Pharmacology. 2020. frontiersin.org
9. Mak KK, Wong YH, Pichika MR. Artificial intelligence in drug discovery and development. Drug Discovery and Evaluation: Safety and Pharmacokinetic Assays. 2023 Sep 28:1-38. nih.gov
10. Khan MK, Raza M, Shahbaz M, Hussain I, Khan MF, Xie Z, Shah SS, Tareen AK, Bashir Z, Khan K. The recent advances in the approach of artificial intelligence (AI) towards drug discovery. Frontiers in Chemistry. 2024 May 31; 12:1408740. frontiersin.org
11. Coletti S, Bernardi G. Exscalate4CoV: High-Performance Computing for COVID Drug Discovery. 2023. [HTML]
12. Noureldin M. DCAF1 as a Novel Therapeutic Target for Lung Cancer. 2023. utoronto.ca
13. Kolla L, Gruber FK, Khalid O, Hill C, Parikh RB. The case for AI-driven cancer clinical trials–The efficacy arm in silico. Biochimica et Biophysica Acta (BBA)-Reviews on Cancer. 2021 Aug 1;1876(1):188572. sciencedirect.com
14. Poomari Durga K. Intelligent Support for Cardiovascular Diagnosis. Using Traditional Design Methods to Enhance AI-Driven Decision Making. 2024 Jan 10:64. [HTML]
15. Thum T. Animal models and animal-free inno ations for cardio ascular research: current status and routes to be explored. Consensus document of the ESC orking group …. core.ac.uk. . core.ac.uk
16. Chakraborty C, Bhattacharya M, Lee SS, Wen ZH, Lo YH. The changing scenario of drug discovery using artificial intelligence (AI) to deep learning (DL): Recent advancement, success stories, collaborations, and challenges. Molecular Therapy-Nucleic Acids. 2024 Aug 8. cell.com
17. KOLLURI V. A COMPREHENSIVE STUDY ON AIPOWERED DRUG DISCOVERY: RAPID DEVELOPMENT OF PHARMACEUTICAL RESEARCH. International Journal of Emerging Technologies and Innovative Research (www. jetir. org| UGC and issn Approved), ISSN. 2021:2349-5162. researchgate.net

CITATION: Kaggwa Anthony P. AI-Powered Drug Discovery: Accelerating the Development of New Therapies. Research Output Journal of Biological and Applied Science, 2024 3(2):9-12